AR126387A1 - Anticuerpos anti-tnfr2 y usos de estos - Google Patents
Anticuerpos anti-tnfr2 y usos de estosInfo
- Publication number
- AR126387A1 AR126387A1 ARP220101767A ARP220101767A AR126387A1 AR 126387 A1 AR126387 A1 AR 126387A1 AR P220101767 A ARP220101767 A AR P220101767A AR P220101767 A ARP220101767 A AR P220101767A AR 126387 A1 AR126387 A1 AR 126387A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- lcvr
- hcvr
- sequence
- chain variable
- Prior art date
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 12
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 12
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 101100425757 Homo sapiens TNFRSF1B gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 abstract 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219175P | 2021-07-07 | 2021-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126387A1 true AR126387A1 (es) | 2023-10-11 |
Family
ID=84800439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101767A AR126387A1 (es) | 2021-07-07 | 2022-07-06 | Anticuerpos anti-tnfr2 y usos de estos |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4367140A1 (fr) |
| KR (1) | KR20240032985A (fr) |
| CN (1) | CN117980336A (fr) |
| AR (1) | AR126387A1 (fr) |
| AU (1) | AU2022308421A1 (fr) |
| CA (1) | CA3224693A1 (fr) |
| TW (1) | TW202309096A (fr) |
| WO (1) | WO2023281313A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023228082A1 (fr) * | 2022-05-26 | 2023-11-30 | Pfizer Inc. | Anticorps anti-tnfr2 et leurs méthodes d'utilisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3340999A4 (fr) * | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | Anticorps agonistes anti-récepteurs de type ii du facteur de nécrose tumorale |
| WO2019094559A2 (fr) * | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Polypeptides antagonistes de la superfamille des récepteurs du facteur de nécrose tumorale |
| CA3153959A1 (fr) * | 2018-09-18 | 2020-03-26 | Merrimack Pharmaceuticals, Inc. | Anticorps anti-tnfr2 et leurs utilisations |
| WO2020180712A1 (fr) * | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anticorps anti-tnfr2 et leurs utilisations |
| EP3907240A4 (fr) * | 2019-08-02 | 2023-02-22 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Anticorps anti-tnfr2 et son utilisation |
| AU2020348224A1 (en) * | 2019-09-17 | 2022-05-12 | Apexigen, Inc. | Anti-TNFR2 antibodies and methods of use |
| CN112480259B (zh) * | 2021-02-05 | 2021-05-04 | 百奥赛图(北京)医药科技股份有限公司 | 抗tnfr2抗体及其用途 |
-
2022
- 2022-07-06 EP EP22837100.1A patent/EP4367140A1/fr active Pending
- 2022-07-06 KR KR1020247004535A patent/KR20240032985A/ko unknown
- 2022-07-06 CN CN202280060055.4A patent/CN117980336A/zh active Pending
- 2022-07-06 TW TW111125395A patent/TW202309096A/zh unknown
- 2022-07-06 AR ARP220101767A patent/AR126387A1/es unknown
- 2022-07-06 WO PCT/IB2022/000409 patent/WO2023281313A1/fr active Application Filing
- 2022-07-06 CA CA3224693A patent/CA3224693A1/fr active Pending
- 2022-07-06 AU AU2022308421A patent/AU2022308421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202309096A (zh) | 2023-03-01 |
| WO2023281313A1 (fr) | 2023-01-12 |
| CN117980336A (zh) | 2024-05-03 |
| AU2022308421A1 (en) | 2024-01-25 |
| CA3224693A1 (fr) | 2023-01-12 |
| EP4367140A1 (fr) | 2024-05-15 |
| KR20240032985A (ko) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20231067A1 (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| MX2022001260A (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos. | |
| AR126387A1 (es) | Anticuerpos anti-tnfr2 y usos de estos | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| AR115192A1 (es) | Anticuerpos | |
| MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
| MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
| PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano |